AI Can Reliably Predict Efficacy of Immune Checkpoint Inhibitor Therapy
By Elana Gotkine HealthDay Reporter
FRIDAY, Jan. 10, 2025 -- The machine learning system SCORPIO can predict patient outcomes with immune checkpoint inhibitor (ICI) therapy across diverse cancer types and health care settings, according to a study published online Jan. 6 in Nature Medicine.
Seong-Keun Yoo, Ph.D., from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues developed and evaluated SCORPIO utilizing routine blood tests and clinical characteristics from 9,745 ICI-treated patients across 21 cancer types. SCORPIO was trained on data from 1,628 patients across 17 cancer types and tested in internal test sets made up of 2,511 patients across 19 cancer types. External validation was performed on 10 global phase 3 trials with 4,447 patients across six cancer types and in a real-world cohort from Mount Sinai Health System with 1,159 patients across 18 cancer types.
The researchers found that SCORPIO achieved median time-dependent area under the receiver operating characteristic curve (AUC[t]) values of 0.763 and 0.759 in the two internal test sets for predicting overall survival at six, 12, 18, 24, and 30 months, outperforming median AUC(t) values of 0.503 and 0.543 for tumor mutational burden (TMB). For predicting clinical benefit (tumor response or prolonged stability), SCORPIO demonstrated superior predictive performance, with AUC values of 0.714 and 0.641, compared with 0.546 and 0.573 for TMB. Performance in predicting ICI outcomes was maintained in external cohorts, surpassing programmed death-ligand 1 immunostaining.
"Despite its limitations, SCORPIO remains a highly accessible model for predicting ICI efficacy and can aid clinical decision-making when used alongside other assessments," the authors write.
Several authors have a provisional patent application, and three are co-inventors on a patent filed for using TMB to predict immunotherapy response. Several authors also disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted January 2025
Read this next
Exercise Helps Reduce Side Effects From Cancer Treatment
THURSDAY, May 1, 2025 -- Exercise mitigates adverse outcomes associated with cancer and its treatments, according to a review published online April 29 in the British Journal...
Outcomes With Immune Checkpoint Inhibitors Similar for Older, Younger Patients
TUESDAY, April 29, 2025 -- Patients with cancer aged 65 years and older receiving immune checkpoint inhibitors (ICIs) derive similar clinical outcomes as younger patients...
Prevalence of Most Cancer Risk Factors Unchanged Before, After Pandemic
THURSDAY, April 24, 2025 -- Smoking rates continued to decline during the COVID-19 pandemic, but other major risk factors for cancer remained stable, according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.